Disitamab vedotin is primarily used for the treatment of patients with locally advanced or metastatic HER2-overexpressing gastric cancer (including gastroesophageal junction adenocarcinoma) who have previously received at least two systemic chemotherapy regimens. It was first approved in China, offering a new therapeutic option for patients with HER2-positive gastric cancer who have developed resistance to or are intolerant of existing therapies.